Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial
Michiel Zietse(Erasmus MC), Roelof W. F. van Leeuwen(Erasmus MC), Nikki de Rouw(Amphia Ziekenhuis), Esther Oomen‐de Hoop(Erasmus MC Cancer Institute), Leni van Doorn(Erasmus MC), Ron H.J. Mathijssen(Erasmus MC), Frederick W. Thielen(University Medical Center Freiburg), Leontine E A M M Spierings(Alrijne Ziekenhuis), Wouter Dercksen(Radboud University Nijmegen), Birgit C. P. Koch(University Medical Center Groningen), Luuk C Aalders(Erasmus University Rotterdam), Virgil A. S. H. Dalm(Erasmus MC)
Cited by 5
Related Papers
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
|PubMed|2001|752
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345
Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients
|Clinical Cancer Research|2012|164